688176 亚虹医药
2025/09 - 九个月2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)-13.406-17.628-15.524-8.525-12.303
总资产报酬率 ROA (%)-11.389-15.821-14.545-8.256-11.919
投入资产回报率 ROIC (%)-11.957-16.609-15.076-8.472-12.247

边际利润分析
销售毛利率 (%)74.75575.54078.99873.02284.989
营业利润率 (%)-119.305-190.415-2,937.490-948,649.406-5,210,058.993
息税前利润/营业总收入 (%)-118.239-199.958-3,197.334-1,037,721.275-5,122,199.049
净利润/营业总收入 (%)-120.629-191.504-2,914.455-944,804.606-5,135,637.810

收益指标分析
经营活动净收益/利润总额(%)105.377105.337107.943125.221108.671
价值变动净收益/利润总额(%)-7.534-6.322-6.324-23.476-6.975
营业外收支净额/利润总额(%)1.3220.773-0.623-0.932-1.533

偿债能力分析
流动比率 (X)4.9877.76912.81634.21740.716
速动比率 (X)4.9557.73912.80834.18240.665
资产负债率 (%)19.19711.3649.2133.5832.774
带息债务/全部投入资本 (%)13.2003.6763.065-0.1300.176
股东权益/带息债务 (%)640.9682,548.5543,089.060-76,383.98556,417.493
股东权益/负债合计 (%)422.916779.598984.7232,690.8053,504.356
利息保障倍数 (X)-44.39324.81211.50010.607-558.185

营运能力分析
应收账款周转天数 (天)93.53761.240113.751141.021342.000
存货周转天数 (天)43.43227.202274.394168,675.3492,100,090.830